These findings collectively underscore MST1 as a promising therapeutic target for modulating NAFLD/NASH progression through its regulatory effects on cholesterol biosynthetic pathways and inflammatory–fibrotic cascades. This evidence concerns the gene MST1 and metabolic dysfunction-associated steatotic liver disease.